Products

Gvoke HypoPen^® is the first FDA-approved autoinjector for very low blood sugar that is premixed and ready to go. It is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in adults and children ages 2 years and above with diabetes. It is available in both pediatric (0.5mg/0.1mL) and adult (1.0mg/0.2mL) doses.

Ogluo^®** (glucagon injection) received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2020 and the European Commission (EC) granted the marketing authorization on 11 February 2021. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Ogluo on April 29, 2021. Ogluo is indicated for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

**Xeris has an exclusive agreement with Tetris Pharma Limited, a subsidiary of Arecor Therapeutics plc, for the commercialization of Ogluo® in the European Economic Area, United Kingdom, and Switzerland.

RECORLEV^® is a prescription medicine used to treat high cortisol (endogenous hypercortisolemia) levels in adult patients with Cushing’s Syndrome (CS) who cannot have surgery or who have had surgery that did not cure their Cushing’s Syndrome. 

Limitations of Use 
It is not known if RECORLEV^® is safe and effective for the treatment of fungal infections. RECORLEV® is not to be used for treatment of fungal infections.